These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8116185)

  • 1. In vitro potency testing of inactivated biologics: current situation in the E.E.C.
    Soulebot JP; Milward F; Prevost P
    Vet Microbiol; 1993 Nov; 37(3-4):241-51. PubMed ID: 8116185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro potency assays for nonreplicating veterinary vaccines: comparison to in vivo assays and considerations in assay development.
    Levings RL; Henderson LM; Metz CA
    Vet Microbiol; 1993 Nov; 37(3-4):201-19. PubMed ID: 8116182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of a biological reference preparation for hepatitis A vaccine (inactivated, non-adsorbed).
    Stalder J; Costanzo A; Daas A; Rautmann G; Buchheit KH
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):15-29. PubMed ID: 20223187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced process monitoring: the ultimate alternative.
    Neeleman R; Beuvery C
    Dev Biol (Basel); 2002; 111():273-82. PubMed ID: 12678250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality assurance of C. perfringens epsilon toxoid vaccines--ELISA versus mouse neutralisation test.
    Rosskopf-Streicher U; Volkers P; Noeske K; Werner E
    ALTEX; 2004; 21 Suppl 3():65-9. PubMed ID: 15057410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-dose serological assay suitable to quantify the potency of inactivated rabies vaccines for veterinary use.
    Krämer B; Kamphuis E; Hanschmann KM; Milne C; Daas A; Duchow K
    Biologicals; 2013 Nov; 41(6):400-6. PubMed ID: 24144483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Batch potency testing of inactivated erysipelas vaccines by ELISA--development, validation and implementation.
    Rosskopf-Streicher U; Johannes S; Gyra H; Beckmann R; Cussler K
    Dev Biol (Basel); 2002; 111():153-8. PubMed ID: 12678235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calibration of the Ph. Eur. Biological Reference Preparation (BRP) for tetanus vaccine (adsorbed) batch 3.
    Tierney R; Hockley J; Rigsby P; Terao E; Daas A; Buchheit KH; Sesardic D
    Pharmeur Bio Sci Notes; 2011 Jun; 2011(1):1-26. PubMed ID: 21619853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refinement, reduction, and replacement of animal use for regulatory testing: current best scientific practices for the evaluation of safety and potency of biologicals.
    Hendriksen CF
    ILAR J; 2002; 43 Suppl():S43-8. PubMed ID: 12388851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release potency tests of hepatitis vaccines.
    Descamps J; Mary A; Rommel E; Anhoury ML; De Neys R; Duchêne M
    Dev Biol Stand; 1999; 101():289-94. PubMed ID: 10566803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A step forward in the quality control testing of inactivated rabies vaccines - extensive evaluation of European vaccines by using alternative methods to the in vivo potency tests.
    Servat A; Kempff S; Brogat V; Litaize E; Schereffer JL; Cliquet F
    Altern Lab Anim; 2015 Mar; 43(1):19-27. PubMed ID: 25802995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of the European Pharmacopoeia Biological Reference Preparation (Ph. Eur. BRP) for hepatitis A vaccine type B (Aventis Pasteur) batch 2.
    Buchheit KH; Daas A
    Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):95-108. PubMed ID: 12448033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The target animal safety test--is it still relevant?
    Advisory Group on Alternatives to Animal Testing in Immunobiologicals
    Biologicals; 2002 Dec; 30(4):277-87. PubMed ID: 12474863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The status of eye irritancy testing: a regulatory perspective.
    Wilcox NL
    Lens Eye Toxic Res; 1992; 9(3-4):259-71. PubMed ID: 1301785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three Rs potential in the development and quality control of pharmaceuticals.
    Hartung T
    ALTEX; 2001; 18 Suppl 1():3-13. PubMed ID: 11854852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collaborative study for the establishment of erysipelas ELISA coating antigen. European Biological Reference Preparation batch no. 1.
    Cussler K; Rosskopf-Streicher U; Volkers P; Milne C
    Pharmeuropa Spec Issue Biol; 2001 Aug; 2001(1):75-88. PubMed ID: 11705102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The validation of potency tests: hurdles identified by EMA/CVMP/IWP.
    Woodland R
    Dev Biol (Basel); 2012; 134():69-73. PubMed ID: 22888597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A proposal for reforming psychologists' training in France and in the European Union].
    Bouchard JP
    Encephale; 2009 Feb; 35(1):18-24. PubMed ID: 19250989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern science for better quality control of medicinal products "Towards global harmonization of 3Rs in biologicals": The report of an EPAA workshop.
    Schutte K; Szczepanska A; Halder M; Cussler K; Sauer UG; Stirling C; Uhlrich S; Wilk-Zasadna I; John D; Bopst M; Garbe J; Glansbeek HL; Levis R; Serreyn PJ; Smith D; Stickings P
    Biologicals; 2017 Jul; 48():55-65. PubMed ID: 28596049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.